Case Report of Fibrolamellar Hepatocarcinoma, a Rare Tumor of Young Adults
DOI:
https://doi.org/10.22516/25007440.441Keywords:
Fibrolamellar hepatocellular carcinoma, hepatocellular carcinoma, hepatectomy, hepatic neoplasiaAbstract
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma (HCC) which occurs most often in young adults without regard to sex. It develops in its characteristic way on a previously healthy liver. The classical presentation is a palpable mass in the right upper quadrant, pain, and weight loss.
In the absence of a prior history of liver disease, it is usual to find a large advanced neoplasia which has characteristic findings in a CT scan or MRI. A high percentage of cases can be diagnosed solely with images.
The best treatment for this type of tumor is surgical resection which provides a 5-year survival rate of 58% to 82% but with very high rates of relapse. In published studies rates of relapse vary between 33% and 100%.
We report the case of a young patient with no history of liver disease in which fibrolamellar hepatocellular carcinoma was diagnosed using contrast organ-specific MRI. The tumor was treated with radical surgical resection.
Downloads
References
Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA journal of diseases of children 1956; 91(2): 168-86.
Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980; 46(2): 372-9.
El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004; 39(3): 798-803.
Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointestinal cancer research: GCR 2013; 6(1): 3-9.
Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. The American journal of gastroenterology 2009; 104(10): 2617-24; quiz 25.
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology 2012; 56(4): 908-43.
Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003; 97(8): 2006-12.
Klein WM, Molmenti EP, Colombani PM, Grover DS, Schwarz KB, Boitnott J, et al. Primary liver carcinoma arising in people younger than 30 years. American journal of clinical pathology 2005; 124(4): 512-8.
Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009; 49(3): 821-31.
White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 2012; 142(2): 219-32.
Rageshree Ramachandran SK. Fibrolamellar hepatocellular carcinoma. Diagnostic Histopathology 2010; 16(8): 388-96.
Asrani SK, LaRusso NF. Fibrolamellar hepatocellular carcinoma presenting with Budd-Chiari syndrome, right atrial thrombus, and pulmonary emboli. Hepatology 2012; 55(3): 977-8.
Stevens WR, Johnson CD, Stephens DH, Nagorney DM. Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management. AJR American journal of roentgenology 1995; 164(5): 1153-8.
Chun YS, Zimmitti G. Fibrolamellar variant of hepatocellular carcinoma. Recent results in cancer research Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2013; 190: 101-10.
Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D’Angelica M, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006; 106(6): 1331-8.
Friedman AC, Lichtenstein JE, Goodman Z, Fishman EK, Siegelman SS, Dachman AH. Fibrolamellar hepatocellular carcinoma. Radiology 1985; 157(3): 583-7.
McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kashitani N, Ros PR. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics : a review publication of the Radiological Society of North America, Inc 1999; 19(2): 453-71.
Elsayes KM, Narra VR, Yin Y, Mukundan G, Lammle M, Brown JJ. Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. Radiographics: a review publication of the Radiological Society of North America, Inc 2005; 25(5): 1299-320.
Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999; 213(2): 352-61.
Elsayes KM, Peterson CM, Menias CO. The central scar: pathophysiology and imaging features. Current problems in diagnostic radiology 2007; 36(6): 247-57.
Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2005; 18(11): 1417-23.
Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Advances in anatomic pathology 2007; 14(3): 217-23.
Weeda VB, Murawski M, McCabe AJ, Maibach R, Brugieres L, Roebuck D, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer 2013; 49(12): 2698-704.
Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. Journal of the American College of Surgeons 2012; 215(6): 820-30.
Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009; 35(6): 617-21.
Ichikawa T, Federle MP, Grazioli L, Marsh W. Fibrolamellar hepatocellular carcinoma: pre- and posttherapy evaluation with CT and MR imaging. Radiology 2000; 217(1): 145-51.
Gras P, Truant S, Boige V, Ladrat L, Rougier P, Pruvot FR, et al. Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Case reports in oncology 2012; 5(1): 169-72.
Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(3): 421-7.
Malouf GG, Brugieres L, Le Deley MC, Faivre S, Fabre M, Paradis V, et al. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer 2012; 118(20): 4981-90.
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
